MicroPoint Bioscience
MicroPoint Bioscience is a Chinese POCT diagnostics company developing microfluidic biochip-based immunoassay and electrochemical coagulation analyzers and reagent cards, serving tier-III hospitals, primary care, veterinary clinics, and home users across approximately 100 countries.
- Company typePrivate
- Founded2007
- HeadquartersBeijing, China
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What MicroPoint Bioscience does
MicroPoint Bioscience (Shenzhen MicroPoint Bioscience Technology Co., Ltd., 微点生物) is a Chinese in-vitro diagnostics company specializing in microfluidic point-of-care testing (POCT) devices and reagents, founded in Shenzhen in 2007. The company positions itself as one of the few global players capable of scaling microfluidic biochip production, building its products around a MEMS-based microfluidic platform that integrates complex laboratory workflows — such as immunoassay and electrochemical detection — onto a single chip requiring only one loading step and no pre-processing.
The company's commercial portfolio is anchored by two product families. The mLabs series is a microfluidic fluorescence immunoassay platform comprising handheld, multi-channel (Smart), and fully automated (I200) analyzers, supporting assays across cardiovascular (cTnI, BNP, NT-proBNP, D-dimer, Lp-PLA2, sST2), inflammation (PCT, CRP, SAA, IL-6), coagulation, reproductive health (AMH), renal injury (NGAL), brain injury (S100β), vitamin D, gastric function, and HbA1c. The qLabs series is an electrochemical coagulation platform including handheld meters, an eStation bedside platform, and the Q3 Vet veterinary analyzer, with test cards for PT/INR, PT/APTT/TT/FIB, and combined panels. Product differentiation rests on proprietary technology including S-channel microfluidic controllers, Nano 3D capture modules, and non-parallel dual-channel assay architecture designed to eliminate the high-dose Hook effect.
The company monetizes through a hybrid razor-and-blade model: instrument placement (mLabs/qLabs analyzers) drives recurring reagent card consumption, with annual production capacity of approximately 70 million test cards across approximately 10,000 square meters of facilities (including near 5,000 square meters of GMP cleanrooms). Distribution is omnichannel — domestic direct sales covering approximately 500 Chinese hospitals (tier-III penetration above 60%), channel partners for primary care, and an international network spanning approximately 100 countries across four continents via Dubai Chamber's "China Innovation Centre" and other regional platforms. The company is VC-backed by Shenzhen Capital Group, Northern Light, Sequoia Capital China, Share Capital, and Qiming Venture Partners, was listed on China's New Third Board in 2016 before delisting, and holds 57 NMPA registrations, 178 EU CE certifications, and ISO 13485 certification from German TÜV.
MicroPoint Bioscience firmographics
Firmographics- Name
- MicroPoint Bioscience
- Legal name
- 深圳微点生物技术股份有限公司
- Website
- https://micropointbio.com.cn
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- MicroPoint Bioscience is a Chinese POCT diagnostics company developing microfluidic biochip-based immunoassay and electrochemical coagulation analyzers and reagent cards, serving tier-III hospitals, primary care, veterinary clinics, and home users across approximately 100 countries.
- Ownership category
- akta.pro rank
MicroPoint Bioscience industry classification
Industry- Product category
- In-Vitro Diagnostics / Point-of-Care Testing
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
- akta.pro secondary industry
- Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
Keywords
Where MicroPoint Bioscience is headquartered
LocationHeadquarters
- HQ city
- Beijing
- HQ country
- China
- HQ region
- Asia
Offices4 records
Markets served
MicroPoint Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- POCT诊断设备和试剂销售: 微点生物通过生产和销售微流控POCT诊断仪器（mLabs系列、qLabs系列、Smart、I200等）及配套微流控芯片试剂盒获利。试剂盒涵盖心血管、炎症、凝血、生殖、传染病等多个检测领域，设备与配套试剂捆绑销售，形成耗材收入。
- 试剂耗材（微流控芯片试剂卡）: 试剂卡年产能近7000万张，试剂卡作为耗材持续为医院、诊所等客户提供检测服务，形成持续性耗材收入。
Go-to-market motion3 records
Distribution channels5 records
Marketing channels6 records
MicroPoint Bioscience product offering
Product offeringCore offering
MicroPoint Bioscience develops, manufactures and commercializes microfluidic-based point-of-care testing (POCT) diagnostic instruments and microfluidic chip reagent kits. The portfolio covers the mLabs fluorescence immunoassay analyzer series (mLabs handheld, I200 fully automated, Smart multi-channel) and the qLabs electrochemical coagulation detection series (qLabs ElectroMeter Plus, qLabs eStation, Q3 Vet veterinary), supported by more than 100 reagent kits spanning cardiac markers, inflammation, coagulation, reproductive health, kidney injury, brain injury, and infectious disease testing, sold to hospitals, clinics and international distributors.
Product overview
MicroPoint Bioscience is a microfluidic-based point-of-care diagnostics company offering integrated POCT solutions. The product portfolio centers on two detection platforms: (1) mLabs Microfluidic Fluorescence Immunoassay Platform comprising the mLabs handheld analyzer, I200 fully automated analyzer, and Smart multi-channel analyzer, capable of detecting cardiac markers, inflammatory markers, coagulation markers, reproductive health markers, and infectious disease markers; and (2) qLabs Electrochemical Coagulation Detection Platform including qLabs ElectroMeter Plus, qLabs eStation, Q3 Vet (veterinary), and various coagulation test cards (PT/INR, Coag Panel 4, PT/APTT Combo). The company produces over 100 reagent products covering cardiovascular (cTnI, BNP, NT-proBNP, D-dimer, Lp-PLA2, sST2), inflammation (PCT, CRP, SAA, IL-6), coagulation (PT, APTT, TT, FIB), reproductive health (AMH), kidney injury (NGAL), brain injury (S100β), and COVID-19 testing. Founded in 2007 with approximately 10,000 square meters of R&D and manufacturing facilities including near 5,000 square meters of GMP-certified clean production workshops.
Differentiator
Problem solved
Functional benefit
Products and services
- mLabs Microfluidic Fluorescence Immunoassay Analyzer Portable microfluidic POCT analyzer for rapid fluorescence immunoassay detection supporting whole blood, serum and plasma samples without centrifugation, with 4-10 minute turnaround time. Designed for clinical settings needing fast, accurate immunoassay results at the point of care.
- I200 Fully Automated Microfluidic Detection Platform Fully automated microfluidic fluorescence immunoassay analyzer providing an integrated testing solution for central laboratories, with 1-minute startup, 24-hour standby, auto-sampling and 135 tests/hour throughput.
- Smart Multi-Channel Microfluidic Fluorescence Immunoassay Analyzer Multi-channel microfluidic analyzer enabling simultaneous detection of multiple assays with continuous testing without waiting, designed for primary care, township health centers and grassroots clinics requiring flexible high-efficiency detection.
- qLabs ElectroMeter Plus Handheld Coagulation Meter Handheld point-of-care coagulation testing device with HD LED touchscreen, wide HCT range adaptation, CV<5% precision, and large-capacity rechargeable battery for primary hospitals and emergency coagulation testing.
- qLabs eStation Coagulation POCT Platform
Companies that use MicroPoint Bioscience
Customer profileNamed customers8 records
Segments5 records
Ideal customer profiles5 records
MicroPoint Bioscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
MicroPoint Bioscience partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- 香港投资推广署core香港子公司受邀出席香港投资推广署与香港中国企业协会联合举办的中资企业新春酒会，香港投资推广署为研发型企业提供人才、税金、产学研配套服务方面的福利政策。
- 香港特区政府引进重点企业办公室（OASES）coreOASES副主任范伟明一行莅临微点生物考察，介绍香港'南金融北科创'双中心布局，为研发型企业提供人才、税金、产学研配套服务，正在就合作项目具体细节进一步商讨。
- 迪拜商会core微点生物CEO徐建群与迪拜商会总裁兼首席执行官默罕默德·阿里·卢塔签订合作备忘录和意向书，成为迪拜商会'中国创新中心'的重要成员企业，该中心将作为海湾合作委员会地区的重要展示窗口和商务拓展平台。
- 清华大学经济管理学院core清华大学经管学院副院长何平一行到访微点生物，双方就孵化培育创新创业人才平台、打造闭环产业链、建设高新技术企业生态等问题进行深入交流，探讨战略合作方案。
- 中国印度尼西亚商会core中国印度尼西亚商会主席Liky Sutikno先生到访微点生物，双方就一项规模传染病筛查产品的联合开发达成初步合作共识，探讨微流控POCT在东南亚市场的战略合作。
- 清华大学x-labcore与清华大学经济管理学院共建创意创新创业教育平台，合作举办SDG开放创新马拉松挑战赛，提供企业导师和创新项目合作，获'金牌合作伙伴'称号，是公司产学研合作的核心伙伴。
- 香港特别行政区政府驻粤经济贸易办事处（驻粤办）core驻粤办副主任叶海崙一行到访微点生物，介绍香港政府对研发型企业在人才、税金、产学研配套服务方面的福利政策，为优秀企业提供香港政府资源一站式服务。
- 深圳湾区中小企业国际创新交流中心minor该中心由工信部中小企业发展促进中心与中国中小企业国际合作协会共同设立，到访微点生物探讨合作，从资金、产业空间、战略布局等方面助力公司发展。
- 特许公认会计师公会（ACCA）minor微点生物获得ACCA培训生发展类认可雇主资格，ACCA将从金融人才招聘、培训、发展，行业发展趋势分析、高端人脉圈子拓展等多方面为公司提供专业领域服务。
- 深圳中小企业服务中心core联合宝安企服中心及三大证券交易所，为微点这类研发属性强的专精特新企业提供融资、上下游产业链对接、以及政府政策传递等服务。
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
MicroPoint Bioscience competitors and assessment
Company assessmentDirect peers
- QuidelOrtho: US-based POCT diagnostics company specializing in rapid immunoassay and molecular diagnostics. Direct competitor in cardiac, inflammation, and infectious disease POCT with overlapping handheld instrument + test strip business model.
- Wondfo Biotech: Leading Chinese POCT diagnostics company with broad cardiac, infectious disease, and women's health menu. Most direct domestic peer competing for tier-3 hospital POCT contracts in China.
- Snibe (Shenzhen New Industries Biomedical): Chinese IVD leader in chemiluminescence immunoassays with growing POCT presence. Competes in similar cardiac and inflammation diagnostic segments with comparable hospital sales model.
- Response Biomedical: Canadian POCT company focused on cardiovascular, infectious disease, and environmental diagnostics with rapid immunochromatographic platform. Comparable scale and product focus on cardiac markers (Troponin I, BNP).
Broad incumbents
- Abbott Point of Care (i-STAT): Abbott's handheld POCT division (i-STAT system) is the global benchmark for bedside blood analysis including cardiac markers and coagulation. Broad incumbent with established global hospital footprint competing in MicroPoint's core segments.
- Mindray Bio-Medical: Major Chinese IVD and medical device manufacturer with broad POCT portfolio including handheld coagulation and immunoassay analyzers. Broad incumbent with deep hospital relationships and global distribution.
- Roche Diagnostics: Global IVD leader with cobas platform spanning central lab and POCT (cobas Liat). Dominates cardiac and sepsis diagnostics globally with extensive clinical evidence and global commercial reach.
Emerging players
- EKF Diagnostics: UK-based diagnostics company with POCT focus on hemoglobin, glucose, and lactate measurement. Emerging player with growing POCT portfolio in similar clinical segments, comparable mid-cap scale.
- Samsung LABGEO (Samsung Medison): Korean POCT platform (IB10 and LABGEO series) for clinical chemistry and immunoassay. Regional player with innovative cartridge-based system competing in similar POCT segments in Asian markets.
- Diagon (Diatron): Hungarian hematology and clinical chemistry reagent/instrument manufacturer. Comparable mid-sized POCT peer with global distribution focus on emerging markets similar to MicroPoint's expansion strategy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
MicroPoint Bioscience compliance and trust
Trust signalCompliance5 records
MicroPoint Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
MicroPoint Bioscience leadership team
Management profileNumber of profiles
Profiles14 records
MicroPoint Bioscience subsidiaries and ownership
Company hierarchySubsidiaries2 records
MicroPoint Bioscience funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MicroPoint Bioscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MicroPoint Bioscience
What does MicroPoint Bioscience do?
MicroPoint Bioscience develops, manufactures and commercializes microfluidic-based point-of-care testing (POCT) diagnostic instruments and microfluidic chip reagent kits. The portfolio covers the mLabs fluorescence immunoassay analyzer series (mLabs handheld, I200 fully automated, Smart multi-channel) and the qLabs electrochemical coagulation detection series (qLabs ElectroMeter Plus, qLabs eStation, Q3 Vet veterinary), supported by more than 100 reagent kits spanning cardiac markers, inflammation, coagulation, reproductive health, kidney injury, brain injury, and infectious disease testing, sold to hospitals, clinics and international distributors.
Is MicroPoint Bioscience a public or private company?
MicroPoint Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.
When was MicroPoint Bioscience founded?
MicroPoint Bioscience was founded in 2007. It employs 101 to 250 people.
Where is MicroPoint Bioscience based?
MicroPoint Bioscience is headquartered in Beijing, China, in the Asia region.
How does MicroPoint Bioscience make money?
Two revenue lines are on record. POCT诊断设备和试剂销售 is the primary driver. The others are 试剂耗材（微流控芯片试剂卡）.
Who are MicroPoint Bioscience's main competitors?
Direct peers on record are QuidelOrtho, Wondfo Biotech, Snibe (Shenzhen New Industries Biomedical) and Response Biomedical. Broad incumbents are Abbott Point of Care (i-STAT), Mindray Bio-Medical and Roche Diagnostics. Emerging players are EKF Diagnostics, Samsung LABGEO (Samsung Medison) and Diagon (Diatron).
Does MicroPoint Bioscience have an API?
No public API is recorded for MicroPoint Bioscience.
What industry is MicroPoint Bioscience in?
MicroPoint Bioscience's product category is In-Vitro Diagnostics / Point-of-Care Testing. Its primary akta.pro industry code is HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays), with a secondary code of HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes). Its NAICS code is 334516 and its SIC code is 2835.